Emerging Infectious Diseases: Getting Ahead of the Curve

David Satcher, M.D., Ph.D.
Centers for Disease Control and Prevention, Atlanta, Georgia, USA

The early history of infectious diseases was characterized by sudden, unpredictable outbreaks, frequently of epidemic proportion. Scientific advances in the late 19th and early 20th centuries resulted in the prevention and control of many infectious diseases, particularly in industrialized nations. Despite these improvements in health, outbreaks of infectious disease continue to occur, and new infections emerge. Since 1987, the National Academy of Science's Institute of Medicine (IOM) has published three reports that have identified erosion of the public health infrastructure among the factors contributing to new and reemerging infectious diseases. In partnership with many public and private organizations in the United States and abroad, the Centers for Disease Control and Prevention (CDC) has developed a strategic plan that addresses the priorities set forth in the IOM reports and serves as a guide for CDC and its partners to combat emerging microbial threats to health. Laboratory-based surveillance, better communication networks, and improvements in the public health infrastructure are the cornerstones of the strategy. Emerging Infectious Diseases, a new periodical produced by CDC, will serve as a forum for exchange of information about incipient trends in infectious diseases, analysis of factors contributing to disease emergence, and development and implementation of prevention measures.

“Nothing in the world of living things is permanently fixed.”
Hans Zinsser—Rats, Lice and History, 1935

Early History of Infectious Diseases
Infectious diseases have plagued humans since the dawn of civilization (1-5). The history of these diseases provides a valuable perspective for evaluating current trends. Humans are presumed to have originated in tropical climates and to have been affected by the same parasitic diseases as other primates in these areas. As available supplies of game diminished, early hunters migrated into temperate zones which were free of tropical parasites. Historians speculate that humans were relatively safe from infectious diseases during that period. Later, however, as agriculture began to provide a substantial portion of the human diet, populations stabilized and grew. Eventually, populations reached a size that would support persistent person-to-person spread of infectious microorganisms. With this newly established mode of transmission, infectious diseases soon became widespread. The exact origins of many infectious agents remain obscure, but with the advent of large populations, humans eventually became the established reservoir of many agents. Infected animals and contaminated food and water were additional sources of infectious microorganisms.

Dissemination of infectious diseases intensified as civilizations progressed. Caravans of traders carried new pathogens to unsuspecting and susceptible populations. Explorers and later conquering armies brought infectious microorganisms to new continents. Stowaway rats and other vermin in the holds of ships traveled down the moorings when the ships docked, bringing fleas, lice, and deadly pathogens to a new world. Sporadic epidemics of plague, smallpox, typhus, and measles ravaged cities, decimated armies, and altered the course of history.

19th Century Discoveries Lead to Infectious Disease Prevention and Control
Control of many infectious diseases became possible with the pioneering work of Robert Koch and Louis Pasteur and the introduction of the germ theory of disease. With bacteriologic cultivation techniques came the first isolation and identification of etiologic agents; virus cultivation and identification became available some decades later. Reservoirs of microorganisms and their life cycles were identified; the epidemiology and natural history of many infectious diseases were described, and successful control measures were initiated. Water
treatment, vector control, and rodent reduction programs followed. By the beginning of the 20th century, the principles of vaccination, established empirically by Edward Jenner more than 100 years earlier, began to be realized in earnest. Antibiotics were discovered, and disinfectants were developed. Collectively, these control measures dramatically decreased the incidence and prevalence of many infectious diseases and their fatality rates. The early part of this century is appropriately regarded as a golden age in public health.

New and Reemerging Infectious Diseases—A Contemporary Problem

Compared with earlier generations, we possess an enormous scientific base, and the rate of acquisition of new information about infectious diseases is at a historic high. Moreover, thanks in large measure to effective childhood immunization programs, including the President’s Childhood Immunization Initiative, many infectious diseases are under control, particularly in the industrialized world. The elimination of smallpox in 1977 stands as a towering achievement in the fight against infectious diseases. However, many infectious diseases have persisted and have displayed a remarkable ability to re-emerge after lengthy periods of stability. Therefore, we must be ever mindful of the cyclical nature of disease trends.

A careful review of infectious disease trends shows a fragile equilibrium between humans and infectious microorganisms. Infectious diseases are still broadly endemic and maintain a large reservoir of agents that have the potential for rapid and widespread dissemination. Infectious diseases remain the leading cause of death worldwide, even as the International Code of Diseases places many infectious diseases in other categories. For example, meningitis and cirrhosis are classified as diseases of the nervous system and liver, respectively, and only 17% of deaths attributable to infections are actually included in the codes for parasitic and infectious diseases (6). In the United States, each year, approximately 25% of physician visits are attributable to infectious diseases, with direct and indirect costs, including those for human immunodeficiency virus (HIV) infection and related illnesses, estimated at more than $120 billion (7).

Persons living in tropical climates are still as vulnerable to infectious diseases as their early ancestors were. Each year more than one million children die of malaria in sub-Saharan Africa alone (8); worldwide, approximately 200 million people have schistosomiasis (9), and each year 35-60 million people contract dengue (10). Moreover, infectious diseases and their attendant problems are not confined to tropical climates. For example, an estimated 600,000 cases of pneumonia occur in the United States each year and cause 25,000 to 50,000 deaths (11). More than 10,000 cases of diphtheria have occurred in Russia since 1993 because of inadequate levels of immunization (12). Despite a century of scientific progress, infectious diseases still cause enormous human suffering, deplete scarce resources, impede social and economic development, and contribute to global instability. The potential for even greater dissemination looms as a continuous threat.

Recent outbreaks underscore the potential for the sudden appearance of infectious diseases in currently unaffected populations. In the United States, contamination of the municipal water supply in Milwaukee, Wisconsin, in 1993 resulted in an outbreak of cryptosporidiosis that affected an estimated 400,000 people; approximately 4,400 persons required hospitalization (13). In the 1990s, epidemic cholera reappeared in the Americas, after being absent for nearly a century; from 1991 through June of 1994 more than one million cases and nearly 10,000 deaths were reported (14). During the 1980s, tuberculosis reemerged in the United States after decades of decline, and drug-resistant strains have made its control more difficult (15, 16). The increasing prevalence of antibiotic-resistant strains of gonococci, pneumococci, enterococci, and staphylococci portend of other serious treatment and control failures. Many other examples of emerging infections could be given (17, 18).

New infectious diseases, often with unknown long-term public health impact, continue to be identified. Table 1 lists major diseases or etiologic agents identified just within the last 20 years (19-41). New agents are regularly added to the list, particularly with the availability of nucleic acid amplification techniques for detecting and identifying otherwise noncultivable microorganisms (40, 42).

In some cases, etiologic agents have been identified as the causes of known diseases or syndromes (e.g., rotavirus, parvovirus, human T-cell lymphotropic viruses I and II (HTLV I/II), and human herpesvirus type 6, (HHV-6)); in other cases, diseases became better recognized or defined (e.g., Legionnaires’ disease, Lyme disease, human ehrlichiosis). Still others are entirely new: with some parallels to medieval times, a previously unknown and deadly disease, acquired immunodeficiency syndrome (AIDS), originated from uncertain sources in one part of the world and became globally disseminated; this time the disease spread at a rate that would have been unthinkable in medieval times. Clearly, the complete history of infectious diseases remains to be written.
Getting Ahead of the Curve

Recent disquieting infectious disease trends have not gone unrecognized, and their similarity to earlier disease trends with immense global consequences has not gone unnoticed. Primary responsibility for addressing new and reemerging infectious diseases rests squarely with the custodians of public health. Indeed, the fundamental maxim of public health must guide current prevention programs: the health of the individual is best ensured by maintaining or improving the health of the entire community. Core functions necessary to ensure the health of the public were defined in the National Academy of Sciences Institute of Medicine (IOM) report on The Future of Public Health (43):

- Assessment of health status, risks, and services
- Development of health policy
- Assurance of quality health services

Surveillance (assessment) is the sine qua non of infectious disease prevention programs; however, for surveillance to be effective it must be specific. Consider, for example, surveillance of viral hepatitis. Only after the various agents of viral hepatitis were identified and specific laboratory testing became available was it possible to explain trends in disease prevalence and establish the epidemiologic principles underlying the different modes of transmission. Specific laboratory testing is also the basis of screening programs that ensure the safety of the blood supply against hepatitis B and hepatitis C. Agent-specific surveillance is a critical component of many immunization programs. Vaccines to Haemophilus influenzae type b, (Hib), for example, were developed in response to laboratory-based surveillance that identified Hib as a major cause of invasive disease in children. The effectiveness of the Hib vaccination campaign in the United States has been dramatic (Figure 1). Similar approaches will ensure appropriate formulation of other developmental vaccines. Monitoring antibiotic resistance is yet another important example of the value of laboratory-based surveillance.

### Table 1. Major Etiologic Agents, Infectious Diseases Identified Since 1973*

<table>
<thead>
<tr>
<th>Year</th>
<th>Agent</th>
<th>Disease</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1973</td>
<td>Rotavirus</td>
<td>Major cause of infantile diarrhea worldwide</td>
<td>19</td>
</tr>
<tr>
<td>1975</td>
<td>Parvovirus B19</td>
<td>Fifth disease; Aplastic crisis in chronic hemolytic anemia</td>
<td>20</td>
</tr>
<tr>
<td>1976</td>
<td>Cryptosporidium parvum</td>
<td>Acute enterocolitis</td>
<td>21</td>
</tr>
<tr>
<td>1977</td>
<td>Ebola virus</td>
<td>Ebola hemorrhagic fever</td>
<td>22</td>
</tr>
<tr>
<td>1977</td>
<td>Legionella pneumophila</td>
<td>Legionnaire's disease</td>
<td>23</td>
</tr>
<tr>
<td>1977</td>
<td>Hantaan virus</td>
<td>Hemorrhagic fever with renal syndrome (HFRS)</td>
<td>24</td>
</tr>
<tr>
<td>1977</td>
<td>Campylobacter sp.</td>
<td>Enteric pathogens distributed globally</td>
<td>25</td>
</tr>
<tr>
<td>1980</td>
<td>Human T-cell lymphotropic virus I (HTLV I)</td>
<td>T-cell lymphoma—leukemia</td>
<td>26</td>
</tr>
<tr>
<td>1981</td>
<td>Staphylococcus toxin</td>
<td>Toxic shock syndrome associated with tampon use</td>
<td>27</td>
</tr>
<tr>
<td>1982</td>
<td>Escherichia coli O157:H7</td>
<td>Hemorrhagic colitis; hemolytic uremic syndrome</td>
<td>28</td>
</tr>
<tr>
<td>1982</td>
<td>HTLV II</td>
<td>Hairy cell leukemia</td>
<td>29</td>
</tr>
<tr>
<td>1982</td>
<td>Borrelia burgdorferi</td>
<td>Lyme disease</td>
<td>30</td>
</tr>
<tr>
<td>1983</td>
<td>Human immunodeficiency virus (HIV)</td>
<td>Acquired immunodeficiency syndrome (AIDS)</td>
<td>31</td>
</tr>
<tr>
<td>1983</td>
<td>Helicobacter pylori</td>
<td>Gastric ulcers</td>
<td>32</td>
</tr>
<tr>
<td>1988</td>
<td>Human herpesvirus-6 (HHV-6)</td>
<td>Roseola subitum</td>
<td>33</td>
</tr>
<tr>
<td>1989</td>
<td>Ehrlichia chaffeensis</td>
<td>Human ehrlichiosis</td>
<td>34</td>
</tr>
<tr>
<td>1989</td>
<td>Hepatitis C</td>
<td>Parenterally transmitted non-A, non-B hepatitis</td>
<td>35</td>
</tr>
<tr>
<td>1991</td>
<td>Guanarito virus</td>
<td>Venezuelan hemorrhagic fever</td>
<td>36</td>
</tr>
<tr>
<td>1992</td>
<td>Vibrio cholerae O139</td>
<td>New strain associated with epidemic cholera</td>
<td>37</td>
</tr>
<tr>
<td>1992</td>
<td>Bartonella (= Rochalimaea) henselae</td>
<td>Cat-scratch disease; bacillary angiomatosis</td>
<td>38, 39</td>
</tr>
<tr>
<td>1993</td>
<td>Hantavirus isolates</td>
<td>Hantavirus pulmonary syndrome</td>
<td>40</td>
</tr>
<tr>
<td>1994</td>
<td>Sabiá virus</td>
<td>Brazilian hemorrhagic fever</td>
<td>41</td>
</tr>
</tbody>
</table>

*Compiled by CDC staff. Dates of discovery are assigned on the basis of the year the isolation or identification of etiologic agents was reported.
surveillance. Within this context, current discoveries of etiologic agents and diseases (Table 1) are reasons for optimism. The potential for improvements in assessment and prevention of these and other newly discovered diseases is reminiscent of the watershed years of Koch and Pasteur.

We cannot overstate the role of behavioral science in our effort to “get ahead of the curve” with emerging infections. Having the science or laboratory technology to control infectious diseases is not enough, unless we can influence people to behave in ways that minimize the transmission of infections and maximize the efforts of medical interventions. For example, even though HIV/AIDS does not have a vaccine or cure, it is almost entirely preventable. For many people, however, reducing the risk for HIV infection and AIDS requires important changes in lifestyle or behavior. We must use our knowledge of human behavior to help people make lifestyle changes and prevent disease.

Another illustration of the need to use behavior science is the problem of antibiotic resistance. To a great extent, this problem is related to the behavior of both physicians and patients. Physicians continue to use antibiotics inappropriately, and patients continue to demand antibiotic treatment when it is not indicated, for example, for the common cold. As society changes and institutions such as day care centers and prisons become more crowded, the spread of infectious diseases is exacerbated. For homeless and drug-dependent populations, completing a 6- to 9-month course of therapy for tuberculosis is difficult, and the failure to complete the therapy increases the risk for drug-resistant tuberculosis in the community.

Microbiologists, infectious disease specialists, and other basic and clinical scientists must collaborate with behavioral scientists in an interdisciplinary effort to prevent and control emerging infections.

The Future of Public Health emphasizes the relationship between a sound public health infrastructure and infectious disease prevention programs. Infrastructure improvements must become a national priority: certainly they are among CDC’s top priorities. Improvements in infectious disease surveillance are particularly needed. Enriching the capacity to respond to urgent threats to health and developing nationwide prevention strategies are also CDC priorities. To combat new and reemerging infectious diseases, CDC, in collaboration with other federal agencies, state and local health departments, academic institutions, professional societies, international organizations, and experts in public health infectious diseases and medical microbiology developed a plan—Addressing Emerging Infectious Disease Threats: A Prevention Strategy for the United States (7). The plan has four major goals:

- **Surveillance and Response**—detect, promptly investigate, and monitor emerging pathogens, the diseases they cause, and the factors influencing their emergence
- **Applied research**—integrate laboratory science and epidemiology to optimize public health practice
- **Prevention and control**—enhance communication of public health information about emerging diseases and ensure prompt implementation of prevention strategies
- **Infrastructure**—strengthen local, state, and federal public health infrastructures to support surveillance and implement prevention and control programs

CDC’s plan provides a framework for the agency to work collaboratively with its many partners to identify and reverse worrisome trends in infectious diseases.

The need for implementing CDC’s plan is urgent, given the extremely dynamic nature of disease trends and the complexity of factors contributing to disease emergence; these were outlined in detail in the 1992 IOM report—Emerging Infections: Microbial Threats to Health in the United States (45) and are discussed in a companion article by Stephen S. Morse, Ph.D., in this issue. The IOM report concludes that infectious diseases must be viewed as but one component of a dynamic and complex global ecology, which is shaped and buffeted by technologic, societal, economic, environmental, and demographic factors.
changes, not to mention microbial change and adaptation.

Clearly, broader coalitions are needed, and communication must improve if we are to "get ahead of the curve." This new periodical is part of the overall strategy to draw worldwide attention to emerging infections and improve communication. Given the multiplicity of factors contributing to disease emergence, Emerging Infectious Diseases (EID) will present relevant concepts from professionals in multiple disciplines and disseminate information about emerging infectious diseases in order to develop and apply ecologically acceptable interventions that will benefit humankind. Prevention and control of new and emerging infectious diseases depend on the participation of scientists and other professionals in the public and private sectors.

CDC will make EID available by print and electronically to facilitate rapid communication. We hope that in the process EID will promote the exchange of infectious disease information through global electronic networks and bulletin boards. Although there are many similarities between our vulnerability to infectious diseases and that of our ancestors, there is one distinct difference: we have the benefit of extensive scientific knowledge. Ultimately, our success in combatting infectious diseases will depend on how well we use available information. A recent report by the Carnegie Commission "Science, Technology, and Government for a Changing World," provides valuable insight in this regard (46). Commenting on the Earth Summit in Rio de Janeiro in 1992, the report emphasizes the need to shift from the "manifestations of environmental changes in the air, land, water, and plant and animal kingdoms to the causes of those changes." Indeed, the advice of that report challenges us all—"our capacity to generate, integrate, disseminate, and apply knowledge will determine the human prospect in the 21st century."

Dr. Satcher is director of the Centers for Disease Control and Prevention, Atlanta, Georgia. He was president of Meharry Medical College, Nashville, Tennessee, from 1982 to 1993 and is a former faculty member of the King-Drew Medical Center and the UCLA School of Medicine, Los Angeles, California.

References
23. McDade JE, Shepard CC, Fraser DW, Tsai TR, Redus MA, Dowd WR, Laboratory Investigation Team. Leg- 
1277: 297-1193. 208.

24. Lee HW, Lee PW, Johnson KM. Isolation of the etio-
297: 1197-1203.

25. Skirrow MB. Campylobacter enteritis: a “new” dis-
77: 7415-9.

26. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna 
137: 298-308.

27. Schlievert PM., Shands KN, Gan BB, Schmid GP, 
143: 509-16.

28. Riley LW, Remis RS, Helgerson SD, et al. Hemor-

29. Kalyanaraman S, Sarangadharan MG, Poiesz B, 
1981; 143:509-16.

30. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, 
1983; 308:681-5.


32. Yamanishi K, Okuno T, Shiraki K, Takahashi M, 


34. Dawson JE, Anderson BE, Fishbein DB, Sanchez J, 

35. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, 
1989; 244:359-61.

36. Salas R, de Manzione N, Tesh RB, Rico-Hesse R, 

37. World Health Organization. Epidemic diarrhea due to 

38. Regnery RL, Anderson BE, Claridge JE III, 
30:265-74.

39. Welch D, Pickett D, Slater L, Steigerwalt AG, 

40. Nichol ST, Spiropoulou CF, Morzunov S, Rollin PE, 
1993; 262:914-7.

41. Lisieux T, Coimbra M, Nassar ES, Burattini MN, de 

42. Relman DA, Falkow S, LeBoit PE, Perkocha LA, 
324:1514.

43. Institute of Medicine. The future of public health. 

44. Berkelman RL, Bryan RT, Osterholm MT, LeDuc JW, 
1994; 264: 368-70.

45. Institute of Medicine. Emerging infections: microbial 
health in the United States. Washington, 

46. Malone TF. The institutions of science and the global 
the concluding report of the Carnegie Commission on 
Science, Technology, and Government. New York: 